Please upgrade your browser.
Metastatic renal cell carcinoma (RCC) has poor outcomes. Metastatic disease is resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Although targeted cancer therapies have improved progression-free survival for RCC they have not yet demonstrated much improvement in overall survival. What next after failure of these drugs?
Exercise can reduce the often debilitating fatigue that cancer patients experience during chemotherapy, new research shows.
In a New York Times Magazine article, Peter Singer asks: "You have advanced kidney cancer. It will kill you, probably in the next year or two. A drug called Sutent slows the spread of the cancer and may give you an extra six months, but at a cost of $54,000. Is a few more months worth that much?" See original New York Times Magazine article: http://tinyurl.com/lb5ek2
Download the National Cancer, Institute Division of Extramural Activities, Annual Report 2008 (in PDF format).
A number of studies have shown that integrated care is positively correlated with improved quality, which is achieved through the coordination of care among specialties, the effective use of information technologybased decision-support tools, and other key aspects of integrated systems.
Joseph is one of the lucky 50 percent of kidney cancer patients who had a scan for another reason when the cancer was detected. So Lee gave Joseph the option to get rid of the cancer with a quick, more simple surgery he pioneered.
Among more than 20 cancer types "likely to be considered" a high priority for TCGA are clear cell renal cell carcinoma and invasive ductal carcinoma of the breast.
Dr. Sabatini discovered mTOR when he was studying the small molecule rapamycin, a compound that was known to have immunosuppressive and anticancer properties. (mTOR stands for mammalian target of rapamycin.) Two derivatives of rapamycin, temsirolimus (Torisel®) and everolimus (Afinitor®), both of which target the mTOR pathway, are now approved for the treatment of kidney cancer.
|Powered by NeonCRM|